FluimediX, a Taastrup, Denmark-based point-of-care diagnostic company, has received a funding of undisclosed amount to continue to develop its NanoCycler™, a diagnostic platform for the measurement of relevant genetic mutations in patients.
The round was led by SEED Capital Denmark, with participation from existing shareholders.
The proceeds of this financing round will be used to develop a diagnostic test for Warfarin™ metabolism, which would deliver important clinical benefits and cost savings to the healthcare system.
The NanoCycler is a point-of-care diagnostic platform that identifies the presence of genetic mutations, also called Single Nucleotide Polymorphisms (SNPs), that are relevant to specific medical conditions in order to aid proper diagnosis and treatment.
Founded in 2003, FluimediX is located at The Danish Institute of Technology, where it has access to innovative micro technology expertise and facilities.